Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neuronal MAPT expression is mediated by long-range interactions with cis-regulatory elements.
Rogers BB, Anderson AG, Lauzon SN, Davis MN, Hauser RM, Roberts SC, Rodriguez-Nunez I, Trausch-Lowther K, Barinaga EA, Hall PI, Knuesel MT, Taylor JW, Mackiewicz M, Roberts BS, Cooper SJ, Rizzardi LF, Myers RM, Cochran JN. Rogers BB, et al. Among authors: davis mn. Am J Hum Genet. 2024 Feb 1;111(2):259-279. doi: 10.1016/j.ajhg.2023.12.015. Epub 2024 Jan 16. Am J Hum Genet. 2024. PMID: 38232730 Free PMC article.
MAPT expression is mediated by long-range interactions with cis-regulatory elements.
Rogers BB, Anderson AG, Lauzon SN, Davis MN, Hauser RM, Roberts SC, Rodriguez-Nunez I, Trausch-Lowther K, Barinaga EA, Taylor JW, Mackiewicz M, Roberts BS, Cooper SJ, Rizzardi LF, Myers RM, Cochran JN. Rogers BB, et al. Among authors: davis mn. bioRxiv [Preprint]. 2023 Apr 11:2023.03.07.531520. doi: 10.1101/2023.03.07.531520. bioRxiv. 2023. Update in: Am J Hum Genet. 2024 Feb 1;111(2):259-279. doi: 10.1016/j.ajhg.2023.12.015 PMID: 37090552 Free PMC article. Updated. Preprint.
An Improved CRISPR/dCas9 Interference Tool for Neuronal Gene Suppression.
Duke CG, Bach SV, Revanna JS, Sultan FA, Southern NT, Davis MN, Carullo NVN, Bauman AJ, Phillips RA 3rd, Day JJ. Duke CG, et al. Among authors: davis mn. Front Genome Ed. 2020 Sep 15;2:9. doi: 10.3389/fgeed.2020.00009. eCollection 2020. Front Genome Ed. 2020. PMID: 34713218 Free PMC article.
Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
Asselah T, Shafran SD, Bourgeois S, Lai CL, Mathurin P, Willems B, Nguyen MH, Davis MN, Huang KC, Svarovskaia E, Osinusi A, McNally J, Brainard DM, Shaikh OS, Tran TT. Asselah T, et al. Among authors: davis mn. J Viral Hepat. 2019 Oct;26(10):1229-1232. doi: 10.1111/jvh.13159. Epub 2019 Aug 4. J Viral Hepat. 2019. PMID: 31216086 Clinical Trial.
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman CAM, Davis MN, Hinestrosa F, Dvory-Sobol H, Huang KC, Osinusi A, McNally J, Brainard DM, McHutchison JG, Thompson AJ, Sulkowski MS; GS-US-342-1553 Investigators. Gane EJ, et al. Among authors: davis mn. Hepatology. 2017 Oct;66(4):1083-1089. doi: 10.1002/hep.29256. Epub 2017 Aug 26. Hepatology. 2017. PMID: 28498551 Clinical Trial.
22 results